Previous Close | 1.9700 |
Open | 1.9500 |
Bid | 1.8700 x 100 |
Ask | 1.9300 x 200 |
Day's Range | 1.8800 - 1.9500 |
52 Week Range | 1.0250 - 2.8500 |
Volume | |
Avg. Volume | 1,634,927 |
Market Cap | 318.085M |
Beta (5Y Monthly) | 0.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2500 |
Earnings Date | May 07, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.68 |
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently completed monotherapy Part 1 of the study were shared in March 2024, and showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 12-weeks post-dose. Part 2 of the study will investigate a single dose of BPL-003 in patients who are
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants.Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours. NEW YOR
Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...